Effect of valsartan or olmesartan addition to amlodipine on ankle edema in hypertensive patients

Introduction The objective of this study was to compare the effect on ankle edema of adding valsartan (V) or olmesartan (O) to amlodipine (A) in the treatment of hypertension. Methods After a 4-week placebo period, 74 adult outpatients with essential hypertension (diastolic blood pressure [DBP] >...

Full description

Saved in:
Bibliographic Details
Published in:Advances in therapy 2010, Vol.27 (1), p.48-55
Main Authors: Fogari, Roberto, Malamani, Gian, Corradi, Luca, Mugellini, Amedeo, Preti, Paola, Zoppi, Annalisa, Derosa, Giuseppe
Format: Article
Language:English
Subjects:
Adult
Aged
Amlodipine - therapeutic use
Ankle Joint
Antihypertensive Agents - administration & dosage
Antihypertensive Agents - therapeutic use
Blood Pressure
Cardiology
Cross-Over Studies
Drug Therapy, Combination
Edema - drug therapy
Endocrinology
Female
Health technology assessment
Heart Rate - drug effects
Humans
Hypertension - drug therapy
Imidazoles - administration & dosage
Imidazoles - therapeutic use
Internal Medicine
Male
Medicine
Medicine & Public Health
Middle Aged
Norepinephrine - blood
Oncology
Original Research
Pharmacology/Toxicology
Prospective Studies
Rheumatology
Tetrazoles - administration & dosage
Tetrazoles - therapeutic use
Valine - administration & dosage
Valine - analogs & derivatives
Valine - therapeutic use
Valsartan
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Introduction The objective of this study was to compare the effect on ankle edema of adding valsartan (V) or olmesartan (O) to amlodipine (A) in the treatment of hypertension. Methods After a 4-week placebo period, 74 adult outpatients with essential hypertension (diastolic blood pressure [DBP] >90 and 140 mmHg) were treated with A 10 mg once daily for 4 weeks. Thereafter, nonresponder patients (DBP >90 mmHg and/or SBP >140 mmHg; n =51) were randomized to receive additional V 160 mg once daily or O 20 mg once daily for 8 weeks in two crossover periods, each separated by a 4-week placebo period. Clinic blood pressure (BP), heart rate, and ankle/foot volume (AFV) were evaluated and blood samples were drawn to evaluate plasma norepinephrine (NE) levels. Results Both V/A and O/A induced a greater SBP/DBP reduction than A monotherapy (−26.4/−20.8 mmHg and −24.4/−19.1 mmHg, respectively; all P
ISSN:0741-238X
1865-8652
DOI:10.1007/s12325-010-0002-0